Skip to main content
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
L. Boni
FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: Updated and overall survival results of the phase II randomized AtezoTRIBE study
AtezoTRIBE (NCT03721653) is a phase II randomized trial in which unresectable mCRC pts were randomized 1:2 to 1st-line FOLFOXIRI/bev [arm A] or FOLFOXIRI/bev/atezo [arm B]. Adding atezo t...
S. Tamberi ;
M. Bensi ;
I. Toma ;
M. De Grandis ;
M. Palermo ;
A. Cappetta ;
Sara Lonardi ;
A. Catteau ;
C. Antoniotti ;
L. Boni ;
F. Marmorino ;
J. Galon ;
V. Conca ;
R. Moretto ;
Filippo Pietrantonio ;
C. Cremolini ;
A. Passardi ;
M. Ambrosini ;
L. Salvatore ;
06/25/2023
Featured Webinar
Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications
Upcoming Events
February 2 – February 5
February 27 – March 1
March 17 – March 19
March 27 – March 30
March 31 – April 2
April 21 – April 24
April 30 – May 4
April 30 – May 5
May 1 – May 3
May 19 – May 21
See Full Calendar